SCHEMBL18092280

SCHEMBL18092280

CCOC(=O)C1CCN(C(=O)OCC)CC1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.49
MAPT P10636 2/20 0.46
THRB P10828 1/20 0.45
ATM Q13315 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ALDH1A1 P00352 6/20 0.44
NOS3 P29474 1/20 0.43
NOS2 P35228 1/20 0.43
CHRM1 P11229 1/20 0.42
TSHR P16473 1/20 0.41
HTT P42858 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11558371 0.92 GAA (0.44) GAAMAPTTHRBATML3MBTL1
SCHEMBL17028515 0.89 MAPT (0.45) GAAMAPTALDH1A1HTTCYP3A4
SCHEMBL23692789 0.89 ALDH1A1 (0.46) GAAMAPTALDH1A1TSHRKMT2A
SCHEMBL7026410 0.89 ALDH1A1 (0.46) GAAMAPTALDH1A1TSHRKMT2A
SCHEMBL17032291 0.89 ALDH1A1 (0.46) GAAMAPTALDH1A1TSHRKMT2A
SCHEMBL18039756 0.89 GAA (0.54) GAAMAPTTHRBATML3MBTL1
SCHEMBL31170124 0.85 SMN1; SMN2 (0.55) MAPTL3MBTL1ALDH1A1HTTCYP3A4
SCHEMBL31170609 0.85 SMN1; SMN2 (0.55) MAPTL3MBTL1ALDH1A1HTTCYP3A4
SCHEMBL20822071 0.82 MAPT (0.41) GAAMAPTALDH1A1TSHRHTT
SCHEMBL12883863 0.79 GAA (0.50) GAAMAPTTHRBATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332478-B2 Manufacture of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol H. LUNDBECK A/S (DK) 2022-05-17 US disclosed
US-11332478-B2 Manufacture of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol H. LUNDBECK A/S (DK) 2022-05-17 US disclosed
CN-107428776-B Production of 4,5,6, 7-tetrahydroisoxazolo [5,4-c ] pyridin-3-ol H.隆德贝克有限公司 2020-10-23 CN disclosed
CN-107428776-B Production of 4,5,6, 7-tetrahydroisoxazolo [5,4-c ] pyridin-3-ol H.隆德贝克有限公司 2020-10-23 CN disclosed
US-20200223865-A1 MANUFACTURE OF 4,5,6,7-TETRAHYDROISOXAZOLO[5,4-C]PYRIDIN-3-OL H. LUNDBECK A/S (DK) 2020-07-16 US disclosed
US-20200223865-A1 MANUFACTURE OF 4,5,6,7-TETRAHYDROISOXAZOLO[5,4-C]PYRIDIN-3-OL H. LUNDBECK A/S (DK) 2020-07-16 US disclosed
US-10626123-B2 Manufacture of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol H. LUNDBECK A/S (DK) 2020-04-21 US disclosed
US-10626123-B2 Manufacture of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol H. LUNDBECK A/S (DK) 2020-04-21 US disclosed
EP-3274331-B1 MANUFACTURE OF 4,5,6,7-TETRAHYDROISOZAXOLO[5,4-C]PYRIDIN-3-OL H LUNDBECK AS (DK) 2020-02-26 EP disclosed
US-20180065984-A1 Manufacture of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol H. LUNDBECK A/S (DK) 2018-03-08 US disclosed
US-20180065984-A1 Manufacture of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol H. LUNDBECK A/S (DK) 2018-03-08 US disclosed
EP-3274331-A1 MANUFACTURE OF 4,5,6,7-TETRAHYDROISOZAXOLO[5,4-C]PYRIDIN-3-OL H. Lundbeck A/S (DK) 2018-01-31 EP disclosed
EP-3274331-A1 MANUFACTURE OF 4,5,6,7-TETRAHYDROISOZAXOLO[5,4-C]PYRIDIN-3-OL H. Lundbeck A/S (DK) 2018-01-31 EP disclosed
WO-2016150953-A1 MANUFACTURE OF 4,5,6,7-TETRAHYDROISOZAXOLO[5,4-C]PYRIDIN-3-OL H. LUNDBECK A/S (DK) 2016-09-29 WO disclosed
WO-2016150953-A1 MANUFACTURE OF 4,5,6,7-TETRAHYDROISOZAXOLO[5,4-C]PYRIDIN-3-OL H. LUNDBECK A/S (DK) 2016-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332478-B2 Manufacture of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol GABRP, GABRD, GABRA5 GAA 4307/4885MAPT 1151/4885THRB 718/4885
US-10626123-B2 Manufacture of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol GABRP, GABRA5, GABRD GAA 4320/4885MAPT 1171/4885THRB 714/4885
US-20200223865-A1 MANUFACTURE OF 4,5,6,7-TETRAHYDROISOXAZOLO[5,4-C]PYRIDIN-3-OL GABRP, GABRD, GABRA5 GAA 4307/4885MAPT 1151/4885THRB 718/4885
US-20180065984-A1 Manufacture of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol GABRP, GABRA5, GABRD GAA 4320/4885MAPT 1171/4885THRB 714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.